These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 12615818)

  • 1. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
    Ruan X; Kubba A; Aguilar A; Mueck AO
    Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cyproterone acetate/ethinyl estradiol combination on periodontal status and high-sensitivity C-reactive protein levels in women with polycystic ovary syndrome: a cross-sectional study.
    Singhal R; Tewari S; Sharma R; Singhal S; Tanwar N; Sangwan A
    Quintessence Int; 2024 Apr; 55(4):274-285. PubMed ID: 38391191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethinylestradiol/Chlormadinone acetate for use in dermatological disorders.
    Gómez Vázquez M; Navarra Amayuelas R; Lamarca M; Baquedano L; Romero Ruiz S; Vilar-Checa E; Iniesta MD
    Am J Clin Dermatol; 2011 Sep; 12 Suppl 1(Suppl 1):13-9. PubMed ID: 21895045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to combined oral contraceptives and risk of venous thromboembolism: a protocol for nested case-control studies using the QResearch and the CPRD databases.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ Open; 2014 Apr; 4(4):e004499. PubMed ID: 24713217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: A retrospective study.
    Yu JH; Moon MK; Ahn HC; Yang YM
    Medicine (Baltimore); 2024 Aug; 103(32):e39055. PubMed ID: 39121320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.
    Sweeney C; Gilsenan A; Calingaert B; Moeller C; Schomakers G; Sok A; Holzmann R; Pisa F
    Pharmaceut Med; 2024 Mar; 38(2):145-156. PubMed ID: 38296916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.
    Spitzer WO
    J Obstet Gynaecol Can; 2003 Dec; 25(12):1011-8. PubMed ID: 14663535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined oral contraceptives: venous thrombosis.
    de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.
    de Medeiros SF
    Reprod Biol Endocrinol; 2017 Dec; 15(1):93. PubMed ID: 29216881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Appropriateness of Cyproterone Acetate/Ethinylestradiol in Primary Care: A Population-Based Study in Italy.
    Lapi F; Simonetti M; Cricelli I; Cricelli C; Cassano N; Vena GA
    Clin Drug Investig; 2017 Aug; 37(8):755-762. PubMed ID: 28434141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome.
    Carmina E
    J Endocrinol Invest; 2013 May; 36(5):358-63. PubMed ID: 23449010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of old, new and emerging medicines on metabolic aberrations in PCOS.
    Bargiota A; Diamanti-Kandarakis E
    Ther Adv Endocrinol Metab; 2012 Feb; 3(1):27-47. PubMed ID: 23148192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008.
    Okoroh EM; Hooper WC; Atrash HK; Yusuf HR; Boulet SL
    Am J Obstet Gynecol; 2012 Nov; 207(5):377.e1-8. PubMed ID: 22959762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the use of oral contraceptives in the management of acne.
    Salvaggio HL; Zaenglein AL
    Int J Womens Health; 2010 Aug; 2():69-76. PubMed ID: 21072299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
    Seaman HE; de Vries CS; Farmer RD
    Hum Reprod; 2003 Mar; 18(3):522-6. PubMed ID: 12615818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
    Seaman HE; de Vries CS; Farmer RD
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):427-36. PubMed ID: 15269926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD.
    Seaman HE; de Vries CS; Farmer RD
    Pharmacoepidemiol Drug Saf; 2003; 12(7):541-50. PubMed ID: 14558177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the use of combined oral contraceptives amongst women with and without acne.
    Seaman HE; de Vries CS; Farmer RD
    Hum Reprod; 2003 Mar; 18(3):515-21. PubMed ID: 12615817
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.